IGF2 signaling can be involved in the transition of steatosis and steatohepatitis to HCC due to downregulation of the tumor suppressor PTEN by IGF2 (Horie et al., 2004; Vinciguerra et al., 2008). This evidence concerns the gene IGF2 and hepatocellular carcinoma.